Dr Andrew Chantry

Dr Andy Chantry

Senior Clinical Lecturer & Consultant Haematologist

Sheffield Myeloma Research Team
University of Sheffield Medical School
Dept of Oncology & Metabolism
Beech Hill Road
Sheffield, S10 2RX

Office: EU22

Tel: + 44 114 215 9003
Fax: + 44 114 2713314

Email: a.d.chantry@sheffield.ac.uk

Biography

Dr Andy Chantry is a Senior Clinical Lecturer in the Dept of Oncology, University of Sheffield and leads the Sheffield Myeloma Research Team (SMaRT). He is also an Honorary Consultant Haematologist in the Dept of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust. Since appointment in 2012, he has been awarded over £1.5million in research grants notably from Leukaemia and Lymphoma Research. He has also received substantial industry sponsorship and access to novel compounds from Celgene, Acceleron, Novartis and Amgen.

Research Interests

His principal research interests are anabolic strategies in the treatment of myeloma bone disease and novel strategies to target myeloma tumour. He also has holistic research interests including life with cancer – holistic care and quality of life studies, computational modeling of cancer including using digital simulations and game technology.

Teaching Activity

He lectures on the undergraduate MB ChB course, and informally conducts post graduate teaching of junior doctors and haematology trainees. He is a contributor to MSc in Translational Oncology and the MSc in Health Care Studies.

Professional Activities

Nationally, he is an executive member of the NCRI Myeloma Sub-Group, through which all significant UK Myeloma Clinical Trials are administered. He is also an executive member of the United Kingdom Myeloma Forum, the national body for Haematologists leading clinical and research led developments in the UK. He is a member of the UKMF National Guidelines Group with a special interest in Myeloma Bone Disease. Locally, he is an executive member of the local Cancer Clinical Trial Executive Committee and a member of the Sheffield Experimental Cancer Medicine Centre. He is a member of the Mellanby Centre for Bone Oncology and Insigneo, the Centre for in Silico Medical Research.

Key Publications

May 2017 ‘The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate at inhibiting bone resorption in non-tumor mice and rats and in the treatment of myeloma bone disease in JJN3-NOD/SCID-γ mice.’ M. A. Lawson, A.D. Chantry, J. Paton-Hough, H. R. Evans, D. Lath, M. K. Tsoumpra, M W Lundy, R. Dobson, M. Quijano, A A Kwaasi, J E Dunford, X Duan, J T Triffitt, A Mazur, G Jeans, R G G Russell, F H Ebetino. J Bone Miner Res. doi:10.1002/jbmr.3138. PMID: 28337806

March 2017 ‘Guidelines for the use of imaging in the management of patients with myeloma.’ Chantry AD*, Kazmi M*, Barrington S, Goh, V, Mulholland N, Streetly, M, Lai M Pratt GE Br J Haematol (accepted 20/03/2017)

November 2015 ‘Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.’ Kassen D, Lath D, Lach A, Evans H, Chantry A, Rabin N, Croucher P, Yong KL. Br J Haematol. 2016 Jan;172(1):64-79. doi: 10.1111/bjh.13790. Epub 2015 Nov 2. PMID: 26767468

November 2015 ‘Visual methods, surviving cancer and sexuality: a reflection on negotiating ethical issues and developing academic/artistic partnerships’ Hammond N., Cheeseman M., Chantry AD., Peng, A, Journal of Families, Relationships and Societies: 11/2015; 4(3):483-492.DOI:10.1332/204674315X14381836678553

October 2015 ‘Time to redefine Myeloma.’ Pratt GE, Bowcock S, Chantry AD, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N, Ramasamy K, Snowden JA, Streetly, M, Wechalekar A, Yong K, Bird J Br J Haematol. 2015 Oct; 171(1): 1-10, doi: 10.1111/bjh.13620. Epub 2015 Jul 27. PMID: 26221971

September 2015 ‘Osteolytica, bespoke osteolytic lesion analysis software substantially improves the accuracy and utility of cancer-induced osteolytic lesion analysis’ Evans H, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Richmond P and Chantry AD Bone. 2015 Oct 8;83:9-16. doi: 10.1016/j.bone. PMID: 26456145

August 2015 ‘A review of current murine models of myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.’ Paton-Hough JM, Chantry AD & Lawson MA 2014 Bone. 2015 Aug:77;57-68. Doi: 10.1016/j.bone.2015.04.004. Epub2015April11. Review. PMID: 25868800

March 2015 ‘NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease’ Lawson MA, Paton-Hough JM, Evans HM, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD PlosOne 2015 March 13 DOI: 10.1371/journal.pone.01 19546. PMID 25768011

March 2015 ‘Genetics in Myeloma: Genetic Technologies and their Application to Screening Approaches in Myeloma.’ Talley PJ, Chantry AD, Buckle CH 2014 Br Med Bull. 2015 Mar;113(1):15-30. doi: 10.1093/bmb/ldu041. Epub 2015 Feb 6. PMID: 25662536

September 2014 ‘Myeloma bone disease: pathogenesis, current treatments and future targets.’ Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD Br Med Bull 2014 Sep; 111(1): 117-38. doi: 10.1093/bmb/ldu016. PMID 25190762

For a full list of publications please see myPublications